Trial Profile

SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary) ; Alendronic acid
Indications Calcinosis
Focus Therapeutic Use
Acronyms SALTIRE II

Most Recent Events

13 Nov 2023 Results assessing pre-specified secondary analyses of 24-month change in coronary and ascending aorta calcium scores and 12-month change in coronary and aortic 18F-NaF activity ,presented at the American Heart Association Scientific Sessions 2023.
29 Aug 2022 Results (n=136) of post-hoc analysis assessing fibro-calcific aortic valve thickening in patients with aortic valve stenosis and its reproducibility, associations with echo parameters of AS severity and disease progression presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
29 Apr 2021 Results published in the Circulation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com